[go: up one dir, main page]

MX2017010341A - Terapia para cancer con un parvovirus combinado con bevacizumab. - Google Patents

Terapia para cancer con un parvovirus combinado con bevacizumab.

Info

Publication number
MX2017010341A
MX2017010341A MX2017010341A MX2017010341A MX2017010341A MX 2017010341 A MX2017010341 A MX 2017010341A MX 2017010341 A MX2017010341 A MX 2017010341A MX 2017010341 A MX2017010341 A MX 2017010341A MX 2017010341 A MX2017010341 A MX 2017010341A
Authority
MX
Mexico
Prior art keywords
bevacizumab
cancer therapy
parvovirus
combined
parvovirus combined
Prior art date
Application number
MX2017010341A
Other languages
English (en)
Other versions
MX381598B (es
Inventor
Wick Wolfgang
Geletneky Karsten
Rommelaere Jean
Wick Antje
DAHM Michael
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of MX2017010341A publication Critical patent/MX2017010341A/es
Publication of MX381598B publication Critical patent/MX381598B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe una composición farmacéutica que comprende (a) un parvovirus y (b) bevacizumab, y el uso de dicha composición para tratamiento contra el cáncer, por ejemplo, un tumor sólido.
MX2017010341A 2015-02-11 2016-02-10 Combinación farmacéutica que comprende un parvovirus y bevacizumab. MX381598B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15154629.8A EP3056216B1 (en) 2015-02-11 2015-02-11 Cancer therapy with a parvovirus combined with bevacizumab
PCT/EP2016/025008 WO2016128146A1 (en) 2015-02-11 2016-02-10 Cancer therapy with a parvovirus combined with bevacizumab

Publications (2)

Publication Number Publication Date
MX2017010341A true MX2017010341A (es) 2018-06-06
MX381598B MX381598B (es) 2025-03-12

Family

ID=52544294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010341A MX381598B (es) 2015-02-11 2016-02-10 Combinación farmacéutica que comprende un parvovirus y bevacizumab.

Country Status (16)

Country Link
US (2) US10813959B2 (es)
EP (2) EP3056216B1 (es)
JP (2) JP6586168B2 (es)
KR (2) KR102013405B1 (es)
CN (1) CN107405400B (es)
AU (1) AU2016218575B2 (es)
BR (1) BR112017014189A2 (es)
CA (2) CA3054511C (es)
DK (2) DK3056216T3 (es)
ES (2) ES2622983T3 (es)
IL (1) IL253962B (es)
MX (1) MX381598B (es)
NZ (1) NZ734750A (es)
RU (1) RU2679442C1 (es)
WO (1) WO2016128146A1 (es)
ZA (2) ZA201705905B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
AU2018282735A1 (en) 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
CN112004545B (zh) * 2018-04-20 2025-01-21 香港大学 免疫-溶瘤的经修饰的痘苗天坛病毒和治疗癌症的方法
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
CN117070477A (zh) * 2022-05-10 2023-11-17 纽伦捷生物医药科技（上海）有限公司 重组溶瘤病毒的重编程的功能性片段、组合及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7179456B2 (en) 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
BRPI0518105A (pt) * 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
WO2006075165A1 (en) * 2005-01-13 2006-07-20 Btg International Limited Combination of oncolytic viruses with angiogenesis inhibitors
WO2009011924A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2082745B1 (en) * 2007-12-28 2012-12-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cancer therapy with a parvovirus combined with chemotherapy
EP2266587A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oncolytic virotherapy for prevention of tumor recurrence
EP2366398A1 (en) 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
WO2012058673A2 (en) * 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors

Also Published As

Publication number Publication date
JP2019203027A (ja) 2019-11-28
CA3054511C (en) 2022-03-22
US20180028583A1 (en) 2018-02-01
CA2971808A1 (en) 2016-08-18
AU2016218575B2 (en) 2019-01-31
CA3054511A1 (en) 2016-08-18
IL253962B (en) 2020-10-29
NZ734750A (en) 2018-08-31
ZA201705905B (en) 2018-11-28
MX381598B (es) 2025-03-12
JP2018508482A (ja) 2018-03-29
CN107405400A (zh) 2017-11-28
US20210060102A1 (en) 2021-03-04
IL253962A0 (en) 2017-10-31
RU2679442C1 (ru) 2019-02-11
ES2622983T3 (es) 2017-07-10
CA2971808C (en) 2019-11-12
ES2971250T3 (es) 2024-06-04
KR20170132733A (ko) 2017-12-04
EP3256162B1 (en) 2023-12-06
ZA201805736B (en) 2019-11-27
AU2016218575A1 (en) 2017-07-13
CN107405400B (zh) 2021-03-02
US10813959B2 (en) 2020-10-27
KR102013405B1 (ko) 2019-10-21
DK3256162T3 (da) 2024-02-19
BR112017014189A2 (pt) 2018-03-06
EP3056216A1 (en) 2016-08-17
JP6586168B2 (ja) 2019-10-02
EP3056216B1 (en) 2017-02-01
DK3056216T3 (en) 2017-05-08
KR20190099097A (ko) 2019-08-23
WO2016128146A1 (en) 2016-08-18
EP3256162A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
MX2019009114A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa